Country
United Kingdom
AstraZeneca Plc has voluntary withdrawn a bladder cancer indication for its checkpoint inhibitor Imfinzi (durvalumab) in the US, which was given an accelerated approval in 2017 but failed to show the required efficacy in a follow-up
Full text available to subscribers only. Click here for information on subscribing to MedNous.